Geo-enabled detect and respond system for antimalarial resistance in Ghana: GDRS - Ghana

加纳的抗疟药耐药性地理检测和响应系统：GDRS - 加纳

• 批准号: 10713339
• 负责人: Alash'le G. Abimiku
• 金额: --
• 依托单位: AKROS RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-11 至 2024-02-22
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10713339
• 关键词: Africa; African; Anti-malarial drug resistance; Antimalarials; Area; Blood; Cellular biology; Collaborations; Communities; Containment; Data; Data Science; Decision Making; Dryness; Early Diagnosis; Epidemiology; Field Workers; Genetic; Genomics; Geography; Ghana; HIV; Household; Human; Intervention; Investigation; Laboratories; Laboratory Research; Link; Malaria; Modeling; Molecular; Monitor; Nigeria; Patients; Pattern; Pharmaceutical Preparations; Plasmodium; Research; Research Personnel; Resistance; Sampling; Spottings; Strategic Planning; System; Translating; Treatment Failure; Vaccines; Visualization; Work; coronavirus disease; data streams; design; drug efficacy; epidemiologic data; genomic data; improved; innovation; insight; member; molecular marker; next generation sequencing; open source; pathogen; programs; research study; response; sociodemographics; spatiotemporal; surveillance data; surveillance network; tool; treatment guidelines; virology

Project summary Antimalarial drug resistance is a continuing challenge in the global effort to control and eliminate malaria. Well designed, rapid and highly granular antimalarial surveillance systems are urgently needed to protect the efficacy of remaining antimalarial treatments and inform discovery of new, effective drugs and vaccines. Molecular markers are useful tools to monitor anti-malarial drug resistance and, if used in routine surveillance, could help to detect and monitor the early emergence of resistance before it translates to treatment failures. This project will address the need for more powerful molecular surveillance through a strategic collaboration between two geographically and scientifically complementary, Africa-based networks - the DS-I Africa INFORM Research Hub and the West African Center for Cell Biology for Infectious Pathogens (WACCBIP). Akros and the Institute for Human Virology Nigeria, both part of the INFORM Research hub, will collaborate with WACCBIP to strengthen Ghana’s malaria genomic surveillance network to include capture of community-level, geo enabled dried blood spot (DBS) samples and expand this network to include additional epidemiologic and genomic data streams across geographies in Africa. This partnership will leverage WACCBIP’s existing genomic surveillance ‘hub-and-spoke’ lab network and integrate the network with the work of the DS-I Africa INFORM Research hub. The deliberate, strategic plan to integrate WACCBIP with partners within DS-I Africa will expand geographic coverage of geospatial surveillance through pivoting the open-source ‘Reveal’ geospatial platform already in use by DS-I Africa. With the use of Reveal, the consortium will geoenable WACCBIP’s existing malaria genomic surveillance network and expand the platform to link DBS data collected at the household level to advanced next generation sequencing (NGS) labs. Through this project, stakeholders will be equipped to visualize and monitor molecular markers of antimalarial resistance captured from the DBS samples, and geospatially align these genomic data to other data streams including epidemiologic, programmatic, and socio-demographic data to inform intervention response. The linking and geoenabling of the existing surveillance network to the Reveal platform will increase granular geospatial and temporal antimalarial resistance insights to guide responsive action and drive epidemiological understanding of antimalarial resistance emergence and spread. We envision this project will provide a model for a) geoenabled community-level genomic surveillance, b) better understanding of the manifestation of antimalarial resistance at a granular level, and c) timely access to critical evidence to guide national decision-making for malaria program response and adaptation.

项目概要 抗疟药物耐药性是全球控制和消除疟疾努力中持续存在的挑战。 迫切需要快速且高度精细的抗疟疾监测系统，以保护剩余药物的功效 分子标记是抗疟治疗和发现新的有效药物和疫苗的有用工具。 监测抗疟疾药物耐药性，如果用于常规监测，可以帮助发现和监测早期疟疾 在耐药性转化为治疗失败之前出现。 该项目将通过双方的战略合作来满足更强大的分子监测的需求 两个在地理和科学上互补的非洲网络 - DS-I Africa INFORM 研究中心 以及西非传染性病原体细胞生物学中心 (WACCBIP) 和人类研究所。 尼日利亚病毒学中心是 INFORM 研究中心的一部分，将与 WACCBIP 合作，加强加纳的疟疾防治工作 基因组监测网络，包括捕获社区级、地理支持的干血斑 (DBS) 样本和 扩展该网络以包括非洲各地的其他流行病学和基因组数据流。 合作伙伴关系将利用 WACCBIP 现有的基因组监测“中心辐射”实验室网络并整合该网络 DS-I 非洲 INFORM 研究中心的工作。 将 WACCBIP 与 DS-I Africa 合作伙伴整合的深思熟虑的战略计划将扩大地理覆盖范围 通过使用 DS-I Africa 已经使用的开源“Reveal”地理空间平台来进行地理空间监视。 通过使用 Reveal，该联盟将启用 WACCBIP 现有的疟疾基因组监测网络，并 扩展平台，将家庭层面收集的 DBS 数据链接到先进的下一代测序 (NGS) 实验室。 通过该项目，利益相关者将能够可视化和监测抗疟药耐药性的分子标记 从 DBS 样本中捕获，并将这些基因组数据与其他数据流（包括流行病学、 现有的规划和社会人口统计数据为干预措施提供信息。 Reveal 平台的监测网络将增加精细的地理空间和时间抗疟药抵抗力 指导应对行动并推动流行病学对抗疟药耐药性出现和理解的见解 传播。 我们设想这个项目将为 a) 地理支持的社区级基因组监测提供一个模型，b) 更好的 详细了解抗疟疾耐药性的表现，以及 c) 及时获取关键证据 指导国家疟疾规划应对和适应决策。